General Information of Drug (ID: DM0ZMNI)

Drug Name
REGN6569 Drug Info
Indication
Disease Entry ICD 11 Status REF
Squamous head and neck cell carcinom 2D60.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM0ZMNI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Squamous head and neck cell carcinom
ICD Disease Classification 2D60.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation-inducible TNFR family receptor (TNFRSF18) DTT TNFRSF18 2.39E-03 -0.54 -0.7
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04465487) Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.